Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London HospitalArticle Published on 2021-12-022022-10-31 Journal: Cancers [Category] COVID-19, [키워드] age Alpha variant Analysis anti-cancer treatment anti-cancer treatments association B.1.1.7 B.1.1.7 SARS-CoV-2 variant Cancer co-morbidities co-morbidity Cohort COVID-19 COVID-19 hospitalization COVID-19 in patient COVID-19 pandemic death demographics demonstrated determinant determine Effect evaluated Factor First wave hospital hospitalized patients Immunosuppression increased mortality increased risk independent risk factor London lower mortality metastatic metastatic cancer metastatic disease Mortality outcome Patient patients treated Patients with cancer presenting Retrospective analysis risk risk factor Risk factors SARS-COV-2 infection second wave simple solid cancer systemic systemic anti-cancer therapy United Kingdom University College London variable was performed Wave with COVID-19 [DOI] 10.3390/cancers13236085 PMC 바로가기 [Article Type] Article
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitalsCOVID-19 위기가 전신 암 치료 하에서 전이 된 uro 종양 질환 환자의 의료 서비스에 대한 미치는 영향 : 독일 대학 병원의 다기관 연구Multicenter Study Published on 2021-11-302022-09-10 Journal: World Journal of Urology [Category] COVID19(2023년), MERS, SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected analyses Analysis anti-cancer treatment blood test blood tests Cancer cancer treatment Care Cell coronavirus COVID-19 COVID-19 crisis COVID-19 pandemic COVID19 defined detect deviation disease Effect effect size examined First wave Fisher’s exact tests FIVE focus Follow-up German Germany Impact impacted Medical care metastatic disease MOST multicenter pandemic Patient patients performed receiving remained renal renal cell carcinoma respiratory Result SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly more statistical analysis systemic treatment tendency Treatment university hospital Uro-oncology urothelial carcinoma was determined [DOI] 10.1007/s00345-021-03868-2 PMC 바로가기 [Article Type] Multicenter Study
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic DrugsArticle Published on 2021-08-202022-10-31 Journal: Cancers [Category] COVID-19, [키워드] adjusted age age and gender analyzed anti-cancer treatment antibody Antibody Response anticancer Assessing BNT162b2 BNT162b2 vaccine Cancer cancer patient Cancer patients Chemotherapy Chemotherapy treatment chronic disease COVID-19 COVID-19 vaccine diagnosed drug drugs Effect effective Efficacy facial Gender humoral IgG IgG level immunization Immunotherapy in healthy individual individuals Infection IQR malignant disease manifested measure median Multivariate analysis negative serological response Odds ratio of BNT162b2 participant Patient patients patients treated Protective raise receiving reduced reducing risk risk of COVID-19 SARS-CoV-2 SARS-COV-2 infection second dose Serologic response serological response serology seronegative shown significantly lower significantly more simple social distancing Solid solid malignancy therapy those without cancer treated Treatment two group vaccination was performed worldwide pandemic [DOI] 10.3390/cancers13164191 PMC 바로가기 [Article Type] Article
Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir결합된 컴퓨터 및 세포 스크리닝은 렌바티닙과 렘데시비르에 의한 SARS-CoV-2의 상승적 억제를 확인합니다Animal Published on 2021-07-282022-09-10 Journal: The Journal of General Virology [Category] SARS, 신약개발, 치료제, [키워드] anti-cancer treatment Antiviral compounds antiviral drug approved cellular Combined Compound COVID-19 diclazuril disease severity docking drug drug synergy DrugBank enzyme exhibited functional Future Host host receptor Human identify in vitro independent independent of inhibit inhibit SARS-CoV-2 inhibited Inhibition assays inhibitor lenvatinib management mechanism nucleoside Pazopanib performed protease Protease inhibitor Rapid Remdesivir Replication SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 replication subsequent sunitinib synergistic synergistic effect synergy target the SARS-CoV-2 therapeutic option tyrosine Vero-CCL81 Vero-CCL81 cells Viral viral replication [DOI] 10.1099/jgv.0.001625 PMC 바로가기 [Article Type] Animal
Chemotherapy resumption in breast cancer patient after COVID-19Case Report Published on 2021-07-212022-10-28 Journal: Surgical Case Reports [Category] COVID-19, [키워드] adverse event anti-cancer treatment Breast cancer Cancer cancer patient cancer treatment Case report Chemotherapy clinical information Clinical symptoms Course COVID-19 COVID-19 patients discharge Evaluating Fever had no Hospitalized Infection initial invasive Japanese Patient patients with COVID-19 positive recovering from COVID-19 regimen Resumption risk RT-PCR SAR-CoV-2 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 tested therapy while [DOI] 10.1186/s40792-021-01253-0 PMC 바로가기 [Article Type] Case Report
COVID-19 Vaccine Safety in Cancer Patients: A Single Centre ExperienceArticle Published on 2021-07-162022-10-31 Journal: Cancers [Category] COVID-19, [키워드] adverse event age anaphylaxis anti-cancer treatment approval Cancer Cancer center cancer patient Cancer patients Care Chemotherapy clinical trials collected COVID-19 COVID-19 vaccine Emergency exclusion experience fatigue first dose Follow-up headache Headaches Immunotherapy information less London lung Mild Moderna MOST oncology oncology patient Patient patients Pfizer/BioNTech Phase III trials provide reactogenicity receiving Safety Side effect Side effects simple solid malignancy study period the vaccine tiredness Vaccine was collected [DOI] 10.3390/cancers13143573 PMC 바로가기 [Article Type] Article
Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer CentersArticle Published on 2021-06-112022-10-31 Journal: Cancers [Category] COVID-19, [키워드] accompanied age analyzed anti-cancer treatment Asymptomatic Bacterial infection Cancer Cancer center cancer patient Cancer patients cancer treatment center clinical Clinical course co-morbidities Contact tracing contribute Course courses COVID-19 COVID-19 cases COVID-19 pandemic COVID-19 symptom Critical Deterioration diagnosed diagnostic died Follow-up hematologic heterogenous IMPROVE increased risk investigated knowledge management Mild Modification neoplasm oncologist oncology Patient patients patients with SARS-CoV-2 performance status predominant progressive disease provide risk RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 scenarios scenario secondary significantly increased simple Surveillance survival rate survivor therapeutic strategy therapy Treatment undergo [DOI] 10.3390/cancers13122917 PMC 바로가기 [Article Type] Article
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort studyObservational Study Published on 2021-05-202022-10-04 Journal: BMC Cancer [Category] SARS, 임상, [키워드] acute respiratory syndrome Admission Adult patient Adverse adverse event adverse events ambulatory anti-cancer treatment association Belgium bleeding event cancer patient cancer treatment cohort study Common Terminology Criteria Coronavirus-2 COVID-19 COVID-19 pandemic determine disease eligible patient hematological incidence Infection initial intensive care management MOST neutropenia Non-severe COVID-19 occurred Odds ratio oncology oncology patient outcome oxygen supplementation pandemic pandemic coronavirus Patient patients performance status positive remained reported required Result Risk factors RT-PCR Safe Safety SARS-CoV-2 SARS-CoV-2 RT-PCR test SARS-CoV-2-positive patient SARS-CoV-2-positive patients Serological testing serology severe COVID-19 single-center solid tumor supplementary material systemic systemic anti-cancer therapy Systemic anti-cancer treatment therapy treated Treatment [DOI] 10.1186/s12885-021-08349-8 PMC 바로가기 [Article Type] Observational Study
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution다발성 골수종 및 골수증식성 악성종양 환자에 대한 항SARS-CoV-2 BNT162b2 백신의 5주 면역원성 및 활성 치료에 대한 안전성: 단일 기관의 예비 데이터Clinical Trial Published on 2021-05-172022-08-13 Journal: Journal of Hematology & Oncology [Category] SARS, 임상, 진단, [키워드] anti-cancer treatment anti-CD38 anti-SARS-CoV-2 anti-SARS-CoV-2 IgG approved assumed basal BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine booster Cancer chemiluminescent immunoassay chronic myeloid leukemias Cohort cohorts Committee Concentration Concordance Contagion Control Cutoff daratumumab demonstrated disease dose Endpoint evaluated Evidence family family members FDA first dose Gender geometric mean Geometric mean concentrations geometric mean ratio geometric mean ratios GMC GMCs hematological Hematological malignancy IgG IgG test immunogenic immunogenicity increasing age IRCCS Lazio less leukemia likelihood Linear model logarithm maintain Mann–Whitney test Mask Masks mRNA vaccine Multiple myeloma myeloproliferative malignancies myeloproliferative malignancy myeloproliferative neoplasms neutralization test Neutralizing of BNT162b2 Patient patients plaque Plaque reduction neutralization test positive Preliminary data primary endpoint Protective Quantitative reduce Responder responders response response rates Result risk robust S1/S2 Safety SARS-CoV-2 Serologically Seroprotection rate significantly social distancing Swab swabs Test titers titration Treatment vaccination Vaccination Status was done were excluded [DOI] 10.1186/s13045-021-01090-6 PMC 바로가기 [Article Type] Clinical Trial
Severity of COVID-19 in Cancer patients versus patients without Cancer: A Propensity Score Matching AnalysisResearch Paper Published on 2021-04-242022-10-31 Journal: Journal of Cancer [Category] COVID-19, [키워드] Admission age albumin Analysis anti-cancer treatment Blood urea nitrogen calculated Cancer cancer diagnosis cancer patient Cancer patients Clinical characteristics clinical feature Cohort Comorbidities COVID-19 COVID-19 diagnosis COVID-19 patient COVID-19 patients Critical elevated Gender High-sensitivity C-reactive protein lactate dehydrogenase leukopenia male matching Mild outcome Patient procalcitonin Propensity score propensity score matching PSM recruited Risk factors score survival the Kaplan-Meier method the log-rank test those without cancer Treatment was performed [DOI] 10.7150/jca.54205 PMC 바로가기 [Article Type] Research Paper